The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
It’s not clear if the new program will represent a big shift in how Indiana currently uses its tax credits. In the past few years, life sciences companies — including Eli Lilly and Co., Elanco Animal Health and others — have received state incentives to expand or retain jobs in Indiana.
Seeking to position Indiana as a global leader in agritechnology and life sciences, Gov. Mike Braun unveiled a lofty goal in a public announcement Tuesday morning.
Indiana’s largest life sciences companies and research universities are working to make the state an international leader in chemistry innovation — and they’re ready to launch the first step in a plan called Catalyze Indiana.
Eli Lilly and Co. has launched a platform that offers employers coverage options for obesity care through a partnership with 18 digital health programs.
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Creating opportunities for internships is an essential component of preparing Indiana students for the world of work as well as increasing the chances that we retain these individuals in our state post-graduation.
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and develop drugs at a faster pace.
Elanco Animal Health Inc. stock hit a 52-week high this week after the company posted double-digit revenue growth in the fourth quarter, driven by sales of some of its newest products.
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
